1001 ET - The steep selloff in Sarepta Therapeutics shares following the death of a patient who received its Elevidys gene therapy is likely overdone, Mizuho's Uy Ear says in a brief note. Mizuho says while acute liver injury is a known side effect of Elevidys, this is the first case of acute liver failure leading to death after more than 800 patients have been treated, and that the individual who died had a recent cytomegalovirus infection, which can damage the liver. Mizuho, with an outperform rating and $190 price target on Sarepta, says it still see the Elevidys benefit/risk profile as positive. Sarepta tumbles 23% to $78. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 18, 2025 10:01 ET (14:01 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。